HCV screening in a tertiary french hospital: just do it !

ABSTRACT

Background and aims: Universal screening appears to be the most cost-effective strategy to reach the HCV elimination planned byWHO for 2030. All HCV patients have currently access to treatment. In France HCV screening is based on identification of Risk Factor. The aim of the present studywas to test universal screening strategy in all hospitalized patients. Method: From November 2019 to November 2021, we conduct a prospective, longitudinal monocentric study screening all consent patients for HCV regardless identification of Risk Factor. All HCV Ab positive was followed by HCV RNA screening. All replicating patients were proposed to be treated according to the other pathologies for which the patients were hospitalized. The study was authorized by CPP Toulouse. Because of occurrence COVID 19 pandemics, conducting this studywe identify several limitations leading to the prolongation of inclusion time and to develop adaptive measures such as oral consent. Results: As of September 30, 2021 results are shown in this figure (Figure Presented) HCV Ab + patients seemed older;however this difference is not statistically different. Large part of patients (2/3) were unware of the HCV status. 49 (39.5%) patients come from surgical departments, 38 (30.5%) from the medical department and 37 (30%) are followed in gastroenterology office. All HCV RNA+ patients have been evaluated for treatment. 8 are eradicated, 2 DAA therapy are still on going,1patient refuse treatment (89 years old), 5 patients suffer from HCC and treatmentwas delayed, 2 patients died during palliative management Conclusion: HCVAb prevalence recorded is significantly higher than that observed in the general population in France. However only 15.8% of hospitalized patients have been included. Motivation of all health care workers is essential. Final results of the study will be present at the meeting